Interesting Antibacterial Agents
Keywords:
Quinupristin, dalfopristin, Linezolid, Daptomycin, Tigecycline, Retapamulin, Oritavacin, Dalbavacin, Moxifloxacin, GatifloxacinAbstract
At present, drug resistance has been developed among the microorganism. The effective antimicrobial agents such as Quinupristin/dalfopristin, Linezolid, Daptomycin, Tigecycline, Retapamulin and Quinolone group such as Moxifloxacin and Gatifloxacin are being produced to treat multidrug-resistant gram-positive infections. This is because treatment options are limited. It is therefore necessary to find antimicrobial agents with a new mechanism of action as an alternative treatment of the diseases such as Oritavancin and Dalbavancin. This article will focus on these drugs to treat skin infections, including mode of action, clinical indication, dosage regimens and contraindication. It is essential for the physicians to be aware of using these antibiotics and their indications, dosing and side-effect profiles.
Keywords: Quinupristin/dalfopristin, Linezolid, Daptomycin, Tigecycline, Retapamulin, Oritavancin, Dalbavancin, Moxifloxacin, Gatifloxacin
References
Center for Disease Control and Prevention (CDC). Reduced susceptibility of stapbylococcus aureus to vancomycin--Japan, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:624-6.
Zyvox [package insert]. Kalamazoo, MI. Pharmacia & Upjohn Company; 2000.
Slee AM, Woumola MA, McRiplry RJ, Zajac I, Zawada MJ, Bartholomew PT, et al. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother. 1987;31:1791-7.
Hashemian SMR, Farhadi T, Ganjparvar M. Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther. 2018;12:1759-67.
Perry Cm, Javis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs. 2001;61:525-51.
Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection. Clin infect Dis. 2002;34:1481-90.
Batts DH. Linezolid--a new option fot treating gram-positive infection. Oncolgy (Williston Park). 2000;14(8 Suppl 6):23-9.
Wilson SE, Solomkin JS, Le V, Cammarata SK, Bruss JB. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am J Surg. 2003;185:369-75.
Auckland C, Teare L, Cooke F, Kaufmann ME, Warner M, Jones G, et al. Linezolid-resistant entrocci: report of the first isolates in the United Kingdom. J Antimicrob Chemother. 2002;50:743-6.
Clemett D, Markham A. Linezolid. Drung. 2000;59:815-27.
Barrett JF. Linezolid Pharmacia Crop. Curr Opin Investig Drugs. 2000;1:181-7.
Bryson HM, Spencer CM. Quinupristin-dalfopristin. Drugs. 1996;52:406-15.
Shariati A, Dadashi M, Chegini Z, van Belkum A, Mirzaii M, Khoramrooz SS, et al. The global prevalence of daptomycin, tigecycline, quinupristin/dalfopristin, and linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2020;9:56.
Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999;58:1061-97.
Landman D, Quale JM. Management of infections due to resistant enterococci: a review of therapeutic option. J Antimicrob Chemother. 1997;40:161-70.
Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vencomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother. 1997;39 Suppl A:145-51.
Nichols RL, Graham DR, Barriere SL, Rodgers A, Wilson SE, Zervos M, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infection: two randomized, multicenter studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and skin structure infection Group. J Antimicrob Chemother. 1999;44:263-73.
Fagon J, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med. 2000;161(3 Pt 1):753-62.
Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother. 1999;44:251-61.
Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis. 2001;32:e83-6.
Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guideline. J Antimicrob Chemother. 1999;44 Suppl A:37-46.
Stamatakis MK, Richards JG. Interaction between quinupristin/dalfopristin and cyclosporine. Ann Pharmacother. 1997;31:576-8.
Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis. 2003;36:473-81.
Abbanat D, Macielag M, Bush K. Novel antibacterial agents for the treatment of serious gram-positive infections. Expert Opin Investig Drugs. 2003;12:379-99.
Wesson KM, Lerner DS, Silverberg NB, WeinbergJM. Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. Clin Dermatol. 2003;21:64-70.
Boaretti M, Canepari P, Lleò MM, Satta G. The activity of daptomycin on Enterococcus faecium protoplasts: indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis. J Antimicrob Chemother. 1993;31:227-35.
Canepari P, Boaretti M, Lleò MM, Satta G. Lipoteichoic as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother. 1990;34:1220-6.
Heidary M, Khosravi AD, Khoshnood S, Nasiri MJ, Soleimani S, Goudarzi M. Daptomycin. J Antimicrob Chemother. 2018;73:1-11.
Allen NE, Alborn WE Jr, Hobbs JN Jr. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother. 1991;35:2639-42.
Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 1992;36:318-25.
Garrison MW, Vance-Bryan K, Larson TA, Toscano JP, Rotschafer JC. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother.1990;34;1925-31.
Rybak MJ, Bailey EM, Lamp KC, Kaatz GW. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother. 1992;36;1109-14.
Stephenson J. Researchers describe latest strategies to combat antibiotic-resistant microbes. JAMA. 2001;285:2317-8.
Strahilevitz J, Rubinstein E. Novel agents for resistant gram-positive infections--a review. Int J Infect Dis. 2002;6 Suppl 1:S38-46.
Cubincin [package insert]. Lexington, MA: Cubist Pharmaceuticals; 2003.
Hanberger H, Nilsson LE, Maller R, Isaksson B. Pharmacodynamics of daptomycin and vancomycin on Enteroccoccus faecails and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother. 1991;35;1710-6.
Flüh G, Seifert H, Kaasch AJ. Oritavancin: an update. Future Microbiol. 2018;13:727-9.
U.S. Food and Drug Administration Center for Drug Evaluation and Research. Priority drug and biologic approvals in calendar year 2005. [Accessed 2008 Oct 2]. Available from: www.fda.gov/cder/rdmt/internetpriority05htm.
Cui N, Cai H, Li Z, Lu Y, Wang G, Lu A. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm. 2019;41:1408-13.
Bergeron J, Ammirati M, Danley D, James L, Norcia M, Retsema J, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother. 1996;40;2226-8.
Tigecycline [package insert]. Madison, NJ; Wyeth Pharmaceuticals; 2008.
Eillis-Grosse EJ, Babinchak T, Dartoris N, Rose G, Loh E; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41 Suppl 5:S341-53.
Fraise AP. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance? J Infect. 2006;53:293-300.
Altabax [package insert]. Research Traingle Park, NC. GlaxoSmithKline; 2007.
Meydan S, Marks J, Klepacki D, Sharma V, Baranov PV, Firth AE, et al. Retapamulin-assisted ribosome profiling reveals the alternative bacterial proteome. Mol Cell. 2019;74:481-93.e6.
Abramivits W, Gupta A, Gover M. Altabax (retapamulin ointment), 1%. Skinmed. 2007;6:239-40.
Oranje AP, Chosidow O, Sacchidanand S, Todd G, Singh K, Scangarella N, et al. Topical retapamulin oinment, 1%, versus sodium fusidate onintment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology. 2007;215:331-40.
Barrett JF. Oritavancin. Eli Lilly & Co. Curr Opin Investig Drugs. 2001;2:1039-44.
Mercier RC, Stumpo C, Rybak MJ. Effect of growth phase and pH on the in vitro activities of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. J Antimicrob Chemother. 2002;50:19-24.
Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, Mercier RC, Rybak MJ. Efficasy of LY333328 against experimental methicllin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1998;42:981-3.
Woodford N. Novel agents for the tratment of resistant gram-positive infections. Expert Opin Investig Drugs. 2003;12;117-37.
Wasilewski MM, Disch D, mcGill J, Harris HW, O’Riordan WD, Zeckel ML. Equivalencece of shorter course theapy with oritavancin vs. vancomycin/cephalexin in complicated skin/skin structure infections. Program and abstracts of the 41st Interscience Conferance on Antimicrobial Agents and Chemotheraphy; 2001 Dec 16-19; Chicago, IL, USA. Paper 16-19.
Targanta Therapeutics. Press release. Targanta submits oritavancin new drug application. Cambride, MA. [Accessed 2008 Feb 11]. Available from: http://en.newspeg.com/Targenta-submits-orvita-vancin-new-drug-applicaton-4801102.html.
Bouza E, Valerio M, Soriano A, Morata L, Carus EG, Rodríguez-González C, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51:571-7.
Tarshis GA, Miskin BM, Jones TM, Champlin J, Wingert KJ, Breen JD, et al. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infection: double-blind, multicenter, randomized study. Antimicrob Agents Chemother. 2001;45:2358-62.
Parish LC, Routh HB, Miskin B, Fidelholtz J, Werschler P, Heyd A, et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract. 2000;54:497-503.
Muijsers RB, Javis B. Moxifloxacin in uncomplicated skin and skin structure infections. Drugs. 2002;62:967-73.
Downloads
Published
Versions
- 2026-02-11 (2)
- 2021-04-30 (1)
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพิ์เป็นลิขสิทธิ์ของวารสารโรงพยาบาลชลบุรี